Sulfur Hexafluoride Lipid Microspheres

Phase 2Small molecule

Sulfur Hexafluoride Lipid Microspheres is one of 62 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaRecruiting

UltrasoundRecruiting

Renal Cell CarcinomaPhase 2

Recruiting

UltrasoundPhase 2

Recruiting

Competition

Competitive Landscape

77 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

41 2

Sutent

Pfizer

Approved

70 3

Cabometyx

Bristol-Myers Squibb

Approved

24 4

Keytruda

Merck & Co.

Phase 3

24 5

Yervoy

Bristol-Myers Squibb

Phase 3

20 6

Lenvima

Eisai

Phase 3

17 7

Inlyta

PPrism Pharmaceuticals

Phase 3

24 8

Ixempra

RR-Pharm

Approved

—9

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—10

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Renal Cell Carcinoma

NCT05641935

Q4 2027

Phase 1Recruiting

Ultrasound

NCT06171607

Q1 2028

Phase 2Recruiting

Ultrasound

NCT06261814

Clinical

Trials by Indication[1]

Liver Cancer2 trials

Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03407001·9 enrolled

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn·UUniversity of Southern California·N/A·NCT03300401

Kidney Cancer2 trials

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03907657·15 enrolled

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04021238·25 enrolled

Ultrasound2 trials

Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

Recruiting·Jjohn eisenbrey·Phase 2·NCT06261814·266 enrolled

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

Recruiting·UUniversity of Southern California·Phase 1·NCT06171607·100 enrolled

Renal Cell Carcinoma1 trial

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Recruiting·Jjohn eisenbrey·Phase 2·NCT05641935·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Sulfur Hexafluoride Lipid Microspheres. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfur Hexafluoride Lipid Microspheres compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfur Hexafluoride Lipid Microspheres. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — john eisenbrey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Jjohn eisenbrey

Sulfur Hexafluoride Lipid Microspheres

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Liver Cancer2 trials

Kidney Cancer2 trials

Ultrasound2 trials

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News